Faculty Information - Tomoki Yamatsuji

（Last updated : 2024-09-04 09:12:51）

Tomoki Yamatsuji
Department Kawasaki Medical School Kawasaki Medical School, Department of General Surgery,

Position Professor

■ Journal

1.	2010/07	Responses to surgical stress after esophagectomy:Gene expression of heat shock protein 70,toll-like receptor 4,tumor necrosis factor- and inducible nitric oxide synthase.
2.	2010/07	HSP90 and its inhibitors.
3.	2010/04	RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer.
4.	2022/06/29	Brain and Adrenal Metastasis From Unknown Primary Tumor: A Case Report
5.	2018/10	Descending necrotizing mediastinitis in a healthy young adult.
6.	2018/06	Development of an integrated CRISPRi targeting Np63 for treatment of squamous cell carcinoma.
7.	2017/11	Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.
8.	2017/10	Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.
9.	2017/04	False-Positive Cases of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomographic Scans in Metastasis of Esophageal Cancer
10.	2017/02	A Case of Cholesterol Crystal Embolization with Hemorrhagic Imntestinal Ulcer
11.	2017/02	A case of gastrointestinal stromal tumor (GIST) with peritoneal dissemination - Imatinib re-challenged case-
12.	2017/02	Evaluation of intra-ductal cancer spread using contrast superb micro-vascular imaging(SMI)-a case report-
13.	2016/11	Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study
14.	2016/02	SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma
15.	2015/07	A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.
16.	2015/06	Skin Tube Reconstruction for Esophageal Defects due to Postoperative Complications: Applying a skin flap in esophageal resection and reconstruction
17.	2015/05	Feasibility of oral administration of S-1 as adjuvant chemotherapy in gastric cancer: 4-week S-1 administration followed by 2-week rest vs. 2-week administration followed by 1-week rest
18.	2014/12	A case report of isolated presacral squamous cell carcinoma developd four years after gastrectomy
19.	2014/12	Amino acid signaling in the intestine: The roles of glutamine, leucine and arginine
20.	2013/11	Gastric function preserving esophagectomy for esophageal cancer
21.	2013/08	Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancers
22.	2013/01	Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.
23.	2013/01	Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer
24.	2012/09	Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer.
25.	2012/09	Quality evaluation of medical research by Kawasaki Medical School using bibliometric analysis.
26.	2012/08	Jejunal interposition reconstruction with a stomach preserving esophagectomy improves postoperative weight loss and reflux symptoms for esophageal cancer patients.
27.	2012/07	Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
28.	2012/07	Giant gastrointestinal stromal tumor of the jejunum resected after treatmentwith imatinib
29.	2012/07	Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.
30.	2012/04	Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
31.	2010/12	Targeting KRAS mutation-bearing lung cancer in vivo by pulmonary surfactant-adenovirus-mediated gene transfer.
32.	2010/11	Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.
33.	2010/10	Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.
34.	2010/04	Can it become a potential therapeutic target?
35.	2010/03	Safer glycemic control using isomaltulose-based enteral formula: a pilot randomized crossover trial.
36.	2010/02	The establishment of a new mouse model with orthotopic esophageal cancer showing the esophageal stricture.
Display 5 items
Display all(36)

■ Presentation

1.	2018/09/28	Targeted silencing of SOX2 by an ATF showed antitumor effect in lung and esophageal squamous cell carcinoma （Poster notice）
2.	2018/09/16	Clinical significance of esophagogastroduodenoscopy in patients with esophageal motility disorders （Poster notice）
3.	2018/09/16	Esophageal squamous cell carcinoma is associated with chronic diseases as well as unhealthy lifestyles （Poster notice）
4.	2018/09/16	False positive cases of FDG-PET/CT in metastasis of esophageal squamous cell carcinoma （Poster notice）
5.	2018/09/05	Lymph node metastasis in middle and lower bile duct cancer:Prognostic impact and distribution （Poster notice，General）
6.	2018/06/08	A surgical case of jejunal aberrant pancreas containing high-grade pancreatic intraepithelial neoplasia(PanIN3) （Poster notice，General）
7.	2018/04/16	Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma （Poster notice，General）
8.	2017/06/09	A surgical case of metachronous liver metastasis of hepatoid adenocarcinoma of the stomach （Poster notice，General）
9.	2017/04/03	Development of a novel targeted therapy for malignant mesothelioma carcinoma by a midkine inhibitor. （Poster notice）
10.	2016/10/06	SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma （Speech，General）
11.	2016/05/21	Negative association between esophageal squamous cell carcinoma and gastric mucosal atrophy in the current gastric mucosal condition in Japan
12.	2016/04/18	Sox2 silencing upregulates CDKNIA and suppresses growth of lung squamous cell carcinoma （Poster notice）
13.	2015/04/21	Developmemt of a Sox2 targeting therapy for the treatment of lung squamous cell carcinoma （Poster notice，General）
14.	2015/04/20	Esphageal cancer exhibits a resistance to the chemical of IGF-1R with a maintained Ras-MAPK activity （Poster notice，General）
15.	2014/09/27	Sox2 silencing suppresses cell growth and colony formation of squamous cell lung cancer （Poster notice，Panelist at Symposium/Workshop (Applied)）
16.	2014/04/06	Effective use of MDK/Midkine and MEK inhibitor to treat KRas mutated pulmonary adenocarcinoma cells （Poster notice，General）
17.	2014/04/04	Inhibition of the growth factor midkine by a novel small molecule compound to treat pulmonary adenocarcinoma （Speech，General）
18.	2013/10/05	Inhibition of Midkine by a novel small molecule compound to treat non-small cell lung cancer （Speech，General）
19.	2013/07/26	A new web-based lecture evaluation system at Kawasaki Medical School （Poster notice，General）
20.	2013/06/19	THE USEFULNESS OF THE LEFT LATERAL DECUBITUS POSITION IN THE THORACOSCOPIC ESOPHAGECTOMY
21.	2013/04/08	Development of novel targeted therapies for non-small cell carcinoma by novel Midkine inhibitors （Poster notice，General）
22.	2013/03/01	Feasibility of S-1 for adjuvant chemotherapy of gastric cancer; 4-week S-1 administration followed by 2-week rest vs. 2-week administration followed by 1-week rest （Speech，General）
23.	2012/09/21	Identification of novel Midkine inhibitors for the treatment of non-small cell lung cancer （Speech，General）
24.	2012/04/04	Targeting KRAS lung cancer in vivo by pulmonary surfactant-medicated gene transfer （Poster notice，General）
25.	2012/04/02	HSP90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression （Poster notice，General）
26.	2011/10/03	Anti-tumor effect in lung cancer by a combination treatment of novel HDAC inhibitors : SL142 or SL325 and retinoic acids （Speech，General）
27.	2011/04/04	Antitumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids. （Poster notice）
28.	2011/04/04	Inhibition of mammalian target of rapamycin(mTOR)signaling by Temsirolimus as a potential therapeutic strategy for esophageal cancer treatment. （Poster notice）
29.	2010/09/24	Targeting KRAS lung cancer in vivo by pulmonary surfactant-mediated gene transfer （Panelist at Symposium/Workshop (Other)）
30.	2010/09/23	Experimental approach to control peritoneal dissemination of colon cancer by targeting FAK. （Panelist at Symposium/Workshop (Other)）
31.	2010/09/22	Esophageal cancer exhibits a resistance to a novel IGF-1R inhibitor NVP-AEW541 with a maintained Ras-MAPK activity. （Poster notice，General）
32.	2010/09/01	Analysis of Surgically Resected Case of Barrett's ESophageal Carcinoma. （Poster notice，General）
33.	2010/04/20	The establishment of a new mouse model with orthotopic esophageal cancer showing the esophagostenosis
34.	2010/04/19	N-cadherin down-rgulation has antitumor effects in esophageal cancer
35.	2010/04/18	Adenoviral mediated expression of Omomyc induced growth inhibition and apoptosis in lug cancer expressing Myc
Display 5 items
Display all(35)